Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer

Eur Urol. 2022 Sep;82(3):271-272. doi: 10.1016/j.eururo.2022.04.006. Epub 2022 May 5.

Authors

Samantha Conroy¹, Alana H T Nguyen²

Affiliations

¹ Academic Urology Unit, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK; Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. Electronic address: s.conroy@sheffield.ac.uk.
² Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA.

PMID: 35527064
DOI: 10.1016/j.eururo.2022.04.006

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Drug Discovery
Early Detection of Cancer
High-Throughput Screening Assays*
Humans
Rare Diseases
Urinary Bladder Neoplasms* / drug therapy